The improved factor concentrate

Summary

The current treatment of haemophilia with coagulation protein replacement therapy is both effective and safe. Nevertheless, this therapy requires frequent, repeated intravenous infusions and approximately 25% of treated haemo philia A patients develop antibodies to the replacement protein. Furthermore, the cost and limited availability of current concentrates has restricted access to therapy to less than 30% of the global haemophilia population. With this background, efforts are now underway to develop coagulation concentrates with enhanced biological properties that further improve the quality of care for haemophiliacs. The specific areas of enhancement that are being explored include improved biosynthetic processes, prolonging the circulating half-life and reducing concentrate immuno -genicity. Coincident with these approaches, it is hoped that there will be more widespread availability of these concentrates and that their cost will be contained.

Keywords

Haemophilia - coagulation concentrates

• References

• 1 Barrow RT, Healey JF, Gailani D. et al. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood 2000; 95: 564-568.
• 2 Gale AJ, Radtke KP, Cunningham MA. et al. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost 2006; 4: 1315-1322.
• 3 Hough C, Lillicrap D. Gene therapy for hemophilia: an imperative to succeed. J Thromb Haemost 2005; 3: 1195-1205.
• 4 Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007; 370: 439-448.
• 5 Lenting PJ, Van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-3996.
• 6 Lenting PJ, Van Schooten CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007; 5: 1353-1360.
• 7 Mannucci PM, Tuddenham EG. The hemophilias – from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-1779.
• 8 Pierce GF, Lillicrap D, Pipe SW, Vanden Driessche T. Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment. J Thromb Haemost 2007; 5: 901-906.
• 9 Pipe SW. The promise and challenges of bioengineered recombinant clotting factors. J Thromb Haemost 2005; 3: 1692-1701.
• 10 Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997; 94: 11851-11856.
• 11 Powell JS, Nugent DJ, Harrison JA. et al. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost 2008; 6: 277-283.
• 12 Radtke KP, Griffin JH, Riceberg J, Gale AJ. Di -sulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays. J Thromb Haemost 2007; 5: 102-108.
• 13 Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7: 715-725.
• 14 Sarafanov AG, Makogonenko EM, Andersen OM. et al. Localization of the low-density lipoprotein receptor-related protein regions involved in binding to the A2 domain of coagulation factor VIII. Thromb Haemost 2007; 98: 1170-1181.
• 15 Spira J, Plyushch OP, Andreeva TA, Andreev Y. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 2006; 108: 3668-3673.